Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis nasal therapy over oral metoclopramide.
Monte Rosa Therapeutics (GLUE) shares advanced 42% after the company said it secured a global license deal with Novartis (NVS) to advance therapies for multiple immune-mediated conditions.
Revance Therapeutics (RVNC) shares rose 22%, rebounding from Friday's slide.
Focus Impact Acquisition (FIAC) shares were up 15%, adding to Friday's gains.
MEI Pharma (MEIP) shares increased 12% following a muted session.
Price: 11.75, Change: +6.62, Percent Change: +129.04
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。